The Effect of Azithromycin in Treating Mycoplasma Pneumonia in Children

Abstract

Objective: To discuss and analyze the effect of azithromycin in the treatment of mycoplasma pneumonia in children. Methods: A total of 120 children with mycoplasma pneumonia who were admitted to the Department of Pediatrics of our hospital from January 2022 to December 2022 were selected as the research subjects. They were divided into an azithromycin group and a reference group according to the random number drawing method, with 60 cases in each group. The azithromycin group was treated with azithromycin, and the reference group was treated with conventional treatment. The efficacy of treatment, laboratory indicators, platelet count and D-dimer, and adverse reactions of both groups were compared. Results: The efficacy of the azithromycin group was significantly higher than that of the reference group (P < 0.05). Before treatment, there were no significant differences in the laboratory indicators like ferritin, procalcitonin (PCT), and erythrocyte sedimentation rate (ESR) between the two groups (P > 0.05); after treatment, the laboratory indicators of the azithromycin group were significantly better than those of the reference group (P < 0.05). Before treatment, there was no statistically significant difference in platelet count and D-dimer between the groups (P > 0.05); after medication, the platelet count, and D-dimer in the azithromycin group were significantly better than those in the reference group (P < 0.05). The total incidence of adverse reactions in the azithromycin group was significantly lower than that in the reference group (P < 0.05). Conclusion: Azithromycin is more effective in treating mycoplasma pneumonia in children, and has certain clinical value.